BioMarin Pharmaceutical Inc. (BMRN) is a Biotechnology company in the Healthcare sector, currently trading at $55.47. It has a SharesGrow Score of 82/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BMRN = $146.18 (+163.5% from the current price, the stock appears undervalued). Analyst consensus target is BMRN = $87 (+56.1% upside).
Valuation: BMRN trades at a trailing Price-to-Earnings (P/E) of 30.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.28.
Financials: revenue is $3.2B, +15.4%/yr average growth. Net income is $349M, growing at +51.6%/yr. Net profit margin is 10.8% (healthy). Gross margin is 77.1% (+0.2 pp trend).
Balance sheet: total debt is $643M against $6.1B equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 5.21 (strong liquidity). Debt-to-assets is 8.5%. Total assets: $7.6B.
Analyst outlook: 28 / 41 analysts rate BMRN as buy (68%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 81/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 76/100 (Pass), Future 73/100 (Pass), Income 55/100 (Partial).
